HK inno.N Corporation (KOSDAQ:195940)

South Korea · Delayed Price · Currency is KRW

54,500

0.00 (0.00%)

Apr 28, 2026, 3:30 PM KST

24.86% (1Y)

Market Cap	1.54T
Revenue (ttm)	839.63B
Net Income (ttm)	41.49B
Shares Out	28.33M
EPS (ttm)	1,451.65
PE Ratio	37.54
Forward PE	17.26
Dividend	350.00 (0.64%)
Ex-Dividend Date	Mar 30, 2026

Volume	261,709
Average Volume	145,768
Open	54,200
Previous Close	54,500
Day's Range	52,700 - 55,800
52-Week Range	39,350 - 58,600
Beta	0.65
RSI	61.95
Earnings Date	Apr 28, 2026

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no... [Read more]

Industry Medical Care Facilities

Sector Healthcare

Founded 1984

Employees 1,695

Stock Exchange KOSDAQ

Ticker Symbol 195940

Full Company Profile

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.

Financial Statements

News

There is no news available yet.